---
figid: PMC11278742__medicina-60-01037-g006
figtitle: 'Clinical Pharmacy Initiatives Contribute to the Excellent Efficacy of the
  Dabrafenib/Trametinib Combination for Iodine-Refractory Thyroid Carcinoma: A Case
  Report'
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11278742
filename: PMC11278742__medicina-60-01037-g006.jpg
figlink: /pmc/articles/PMC11278742/figure/F6
number: F6
caption: Intracellular MAPK signaling pathway inhibited by the dabrafenib and trametinib
  combination
papertitle: 'Clinical Pharmacy Initiatives Contribute to the Excellent Efficacy of
  the Dabrafenib/Trametinib Combination for Iodine-Refractory Thyroid Carcinoma: A
  Case Report'
reftext: Charlotte Donz√©, et al. Medicina (Kaunas). 2024 Jul;60(7).
year: '2024'
doi: 10.3390/medicina60071037
journal_title: Medicina
journal_nlm_ta: Medicina (Kaunas)
publisher_name: MDPI
keywords: papillary thyroid carcinoma | oral anticancer therapy | pharmacist-led consultations
  | dabrafenib | trametinib
automl_pathway: 0.9539823
figid_alias: PMC11278742__F6
figtype: Figure
redirect_from: /figures/PMC11278742__F6
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11278742__medicina-60-01037-g006.html
  '@type': Dataset
  description: Intracellular MAPK signaling pathway inhibited by the dabrafenib and
    trametinib combination
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - KRAS
  - HRAS
  - NRAS
  - MTG1
  - SHC1
  - SHC2
  - SHC3
  - SHC4
  - XYLT2
  - SOS1
  - SOS2
  - GRB2
  - H1-2
  - MYC
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - EPHB2
  - MAPK1
  - MAPK3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - RAS
  - GTP
  - Dabrafenib
  - -NH2
  - Trametinib
  - MEK
---
